| # | Drug | Count |
|---|---|---|
| 0 | IPILIMUMAB | 17 |
| 1 | NIVOLUMAB | 17 |
| 2 | CARBOPLATIN | 8 |
| 3 | OXALIPLATIN | 5 |
| 4 | TRASTUZUMAB | 5 |
| 5 | PACLITAXEL | 4 |
| 6 | GEMCITABINE | 3 |
| 7 | GEMCITABINE HYDROCHLORIDE | 3 |
| 8 | PREDNISONE | 3 |
| 9 | ADALIMUMAB | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | NIVOLUMAB AND RELATLIMAB-RMBW | 1 | 0.0019 |
| 1 | ROPEGINTERFERON ALFA-2B | 1 | 0.0005 |
| 2 | IPILIMUMAB | 17 | 0.0004 |
| 3 | NIVOLUMAB | 17 | 0.0002 |
| 4 | DURVALUMAB | 2 | 0.0001 |
| 5 | TRASTUZUMAB | 5 | 0.0001 |
| 6 | OXALIPLATIN | 5 | 0.0001 |
| 7 | CARBOPLATIN | 8 | 0.0001 |
| 8 | GEMCITABINE HYDROCHLORIDE | 3 | 0.0001 |
| 9 | PACLITAXEL | 4 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 1 | Interferon alfa-2b [EPC] | 1 | 0.0005 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 17 | 0.0004 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 18 | 0.0002 |
| 4 | Somatostatin Analog [EPC] | 1 | 0.0001 |
| 5 | Programmed Death Ligand-1 Blocker [EPC] | 2 | 0.0001 |
| 6 | HER2/neu Receptor Antagonist [EPC] | 5 | 0.0001 |
| 7 | Platinum-based Drug [EPC] | 13 | 0.0000 |
| 8 | Microtubule Inhibitor [EPC] | 4 | 0.0000 |
| 9 | Janus Kinase Inhibitor [EPC] | 1 | 0.0000 |